

# COVID-19 or seasonal influenza? How to distinguish in people younger than 65 years old

## — — A retrospective observational cohort study comparing the 2009 pandemic influenza A H1N1 with 2022 SARS-CoV-2 Omicron BA.2 outbreaks in China

Wen Zhong<sup>1 †</sup>, Yisong Wu<sup>1 †</sup>, Wenxiang Yue<sup>1 †</sup>, Jiabin Fang<sup>1</sup>, Baosong Xie<sup>1</sup>, Nengluan Xu<sup>1</sup>, Ming lin<sup>1</sup>, Xiongpeng Zhu<sup>2</sup>, Zhijun Su<sup>3</sup>, Yusheng Chen<sup>1\*</sup>, Hong Li<sup>4,5\*</sup>, Hongru Li<sup>1,6\*</sup>

<sup>1</sup>Department of Respiratory and Critical Care Medicine, Fujian Shengli Medical College, Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China, <sup>2</sup>Department of Hematology, Quanzhou First Hospital, Quanzhou, China, <sup>3</sup>Department of Infectious Diseases, Quanzhou First Hospital, Fuzhou, China, <sup>4</sup>School of Nursing, Fujian Medical University, Fuzhou, China, <sup>5</sup>Fujian Shengli Medical College, Fujian Medical University, Fuzhou, China, <sup>6</sup>Fujian Provincial Key Laboratory of Medical Big Data Engineering, Fujian Provincial Hospital, Fuzhou, China, <sup>†</sup>These authors contributed equally to this work. <sup>\*</sup>These authors are co-corresponding authors.

**Objective:** This study attempted to explore the difference of clinical characteristics in H1N1 influenza infection and SARS-CoV-2 Omicron infection in people younger than 65 years old, in order to better identify the two diseases.

**Methods:** A total of 127 H1N1 influenza patients diagnosed from May 2009 to July 2009 and 3265 patients diagnosed and identified as SARS-CoV-2 Omicron BA.2 variant from March 2022 to May 2022 were admitted in this study. Through the 1 : 2 match based on age (The difference is less than 2 years), gender and underlying diseases, 115 patients with H1N1 infection and 230 patients with SARS-CoV-2 Omicron BA.2 infection (referred to as H1N1 group and Omicron group) were included in the statistics. The clinical manifestations of H1N1 group were compared with those of Omicron group. Logistic regression was performed to analyze the possible independent risk factors of H1N1 group and Omicron group. And multiple linear regression was used to analyze the factors for time for nucleic acid negativization (NAN).

**Results:** The median age of the two groups was 21 [11,26] years. Compared with the H1N1 group, the Omicron group had lower white blood cell count and CRP levels, less fever, nasal congestion, sore throat, cough, sputum and headache, while more olfactory loss, muscle soreness and LDH abnormalities. The Omicron group used less antibiotics and antiviral drugs, and the NAN time was longer (17 [ 14,20] VS 4 [ 3,5],  $P < 0.001$ ). After logistic regression, it was found that fever, cough, headache, and increased white blood cell count were more correlated with the H1N1 group, while muscle soreness and LDH abnormalities were more correlated with the Omicron group. After analyzing the factors of NAN time, it was found that fever (B 1.529, 95 % CI [0.149,2.909],  $P = 0.030$ ) significantly predicted longer NAN time in Omicron patients.

**Conclusion:** This study comprehensively evaluated the similarities and differences in clinical

characteristics between SARS-CoV-2 Omicron infection and 2009 H1N1 influenza infection, which is of great significance for a better understanding for these diseases.

KEYWORDS: SARS-CoV-2, H1N1 influenza, younger, clinical features

## 1. Introduction

The outbreak of COVID-19 in 2019 has created a global pandemic that has infected 664 million patients and killed 6.7 million as of January 22, 2023<sup>[1]</sup>. Because of the strong mutation of COVID-19<sup>[2]</sup>, although we have taken various measures to control the spread of COVID-19, the effect is limited. Alpha variant first appeared, followed by Beta and Delta variant. At present, omicron variant, which was discovered in November 2021, is popular worldwide<sup>[3]</sup>. The data<sup>[4]</sup> show that the disease and death caused by Omicron variant are significantly lower than the previous ones, but it spreads rapidly (R0 value is close to 10). And it has a high reinfection rate<sup>[5]</sup> and strong resistance to existing vaccines<sup>[6]</sup>, which poses severe challenges for epidemic prevention and control.

Influenza virus has long been the most common pathogen in respiratory virus infection<sup>[7]</sup>. In the past century, there have been several influenza pandemics<sup>[8]</sup>, one of which was the H1N1 influenza pandemic that began in the spring of 2009 and caused about 284,400 deaths worldwide.<sup>[9]</sup> The huge death toll from the H1N1 influenza is a wake-up call, while it has many similarities with COVID-19, including similar transmission route, clinical manifestations and transmission range, which provide a reference for dealing with the current global pandemic of the novel coronavirus.

Most previous studies have focused on the difference between wild-type COVID-19 strains and seasonal influenza.<sup>[10,11]</sup> But COVID-19 is evolving, and the difference between Omicron and seasonal flu is less reported. With the arrival of winter and spring, Omicron and H1N1 influenza may occur at any time. In the current environment where most countries cancel normalized nucleic acid testing, it is of great significance for clinicians to understand the identification of the above two diseases. Besides, most of the previous studies focused on elderly patients<sup>[12,13]</sup>, and the difference between Omicron and H1N1 influenza in young patients is rarely reported. Although young patients are often mild<sup>[14]</sup>, they should also be noticed. Therefore, we analyzed the differences between the patients with H1N1 influenza outbreak in 2009 and the patients with Omicron BA.2 outbreak in 2022 (mainly people under 65 years old), in order to help clinicians better identify H1N1 influenza and Omicron BA.2 infection.

## 2. Methods

### Study subject

From May 2009 to July 2009, a total of 127 patients with H1N1 influenza were diagnosed in Fujian Province. Among them, 126 patients were confirmed to be positive by RT-PCR and Real-time RT-PCR of pharyngeal (nasal) test specimens by Fujian Provincial CDC. One patient was diagnosed by tracking serum antibody titer > 1: 4.

And we also recorded a total of 3265 patients with Omicron diagnosed from March 2022 to May 2022. The second-generation whole genome sequencing was performed by Fujian Provincial Center for Disease Control and Prevention (CDC) for the positive SARS-CoV-2 specimens by fluorescence real-time PCR, and it was confirmed that the novel coronavirus epidemic strain in

Quanzhou from March 2022 to May 2022 was Omicron BA.2.

Based on age (The difference is less than 2 years), gender and underlying diseases, we performed a 1 : 2 match between the H1N1 influenza patients and the Omicron patients. Finally, 115 patients with H1N1 and 230 patients with Omicron (referred to as H1N1 group and Omicron group) were included in the statistics.

### **Data involvement**

Clinical and experimental data were collected from electronic medical records using standardized data collection tables. Serological results included whole blood cells, biochemical tests, and C-reactive protein tests. All results were measured within 24 hours after admission. The time of nucleic acid negative (NAN) was defined the time from the beginning of the patient 's course to the first nucleic acid test result being negative.

### **Clinical management**

In the Omicron group, the asymptomatic and mild patients were quarantined in the mobile cabin hospital (MCH) while patients with moderate or severer symptoms were hospitalized for treatment. All H1N1 influenza patients were treated in hospitals. Both groups of patients were treated according to the guidelines<sup>[15,16]</sup>. Nematavir/Ritonavir antiviral therapy is used for patients who meet the indications. Antibiotic therapy is used for patients considering with bacterial infection.

### **Statistical Analysis**

For descriptive analysis, we presented data as median [interquartile range (IQR)] for continuous parameters and as frequency (percentage) for categorical variables. Wilcoxon rank sum testing was employed for numerical variables and Fisher's precision probability test was adopted for categorical variables. Logistic regression was performed to analyze the possible independent risk factors of H1N1 group and Omicron group. And multiple linear regression was used to analyze the influencing factors of NAN time in the two groups. Statistical analysis was performed using SPSS 25.0 data analysis software. A two-tailed P value of less than 0.05 was considered statistically significant.

## **3.Results**

### **Baseline information**

The baseline data of the two groups were shown in TABLE 1. Due to the matching, the median age of both groups was 21[11, 26] years. Among them, 36.52 % were less than 18 years old, 63.48 % were 18-65 years old, and no patients were more than 65 years old. In the gender stratification, men accounted for 56.52 % and women accounted for 43.48 %. And the two groups were not found such as pregnancy, hypertension, diabetes, cardiovascular disease, chronic liver disease, respiratory disease, nervous system disease, metabolic system disease, chronic kidney disease, tumor, etc. Besides, in the Omicron group, the proportion of patients who received 0,1,2, and 3 doses of vaccine was 16.52 %, 6.52 %, 50.87 %, and 26.09 %, respectively.

### **Comparison of clinical characteristics**

Compared with the Omicron group, the H1N1 group had a higher probability of fever (90.43% VS 34.35%;P<0.001), nasal congestion (12.17% VS 1.74%; P < 0.001), sore throat (41.74% VS 21.30%; P<0.001), cough(68.70% VS 36.52%; P<0.001), expectoration(26.09% VS 14.35%;

P=0.012), headache (15.65% VS 0.87%; P<0.001), and a lower probability of olfactory loss (0.00% VS 6.96%; P=0.002) and muscle soreness (4.35% VS 14.78%; P=0.004).(TABLE 2)

Among them, fever (90.43%), cough (68.70%) and sore throat (41.74%) were the most common symptoms in H1N1 group. Similarly, the most common symptoms in Omicron group were cough (36.52%), fever (34.35%) and sore throat (21.30%). (Figure 1)

The H1N1 group had higher white blood cell count (5.49[4.40,6.93] VS 4.85 [3.76,6.45]; P=0.008) and CRP levels (4.60[2.30,10.45] VS 3.23[0.51,6.84]; P < 0.001) (Figure 2), while the LDH abnormal rate (18.26% VS 29.57%; P=0.023) was lower. There was no significant difference in lymphocyte count (1.51 [1.09,2.02] VS 1.58[1.09,2.53]; P=0.161).

In terms of treatment and prognosis, the use of antibiotics (13.91% VS 0.87%; P < 0.001) and antiviral drugs (100.00% VS 0.87%; P < 0.001) in the H1N1 group was significantly higher than that in the Omicron group. And the time of NAN (4[3,5] VS 17[14,20]; P<0.001) in H1N1 group was significantly lower than that in Omicron group.

#### **Analysis of risk factors**

The indicators with P < 0.05 in the above clinical features, laboratory and imaging diagnostics were analyzed, and the Omicron group was used as a reference. The results showed that the H1N1 group was more prone to fever (OR 19.179 , 95%CI [8.82-41.708]; P < 0.001), cough (OR 3.541, 95%CI [1.725-7.270]; P=0.001), headache (OR 15.695, 95%CI [2.288-107.679]; P=0.005), elevated white blood cell count (OR 1.190, 95%CI [1.027-1.378]; P=0.020), and less prone to muscle soreness(OR 0.051, 95%CI [0.013-0.200]; P=0.001) and LDH abnormalities (OR 0.393, 95%CI [0.194-0.795]; P=0.009).(TABLE 3)

#### **Analysis of influencing factors of NAN time**

The results showed that for H1N1 patients, elevated WBC count significantly predicted longer NAN time (B 0.217, 95%CI [0.028,0.406]; P=0.025), while fatigue was associated with shorter one (B -1.589, 95%CI [-2.646, -0.532]; P=0.004). For Omicron patients, fever significantly predicted longer NAN time (B 1.529, 95%CI [0.149,2.909]; P=0.030). (TABLE 4 )

## **4.Discussion**

The novel coronavirus, which began in 2019, is constantly spreading and mutating, having a huge impact on the disease spectrum and bringing huge burden to people worldwide<sup>[17]</sup>. In winter and spring, seasonal influenza virus infection is also very common. It is a respiratory virus different from SARS-CoV-2, but the clinical characteristics of patients infected with it are similar, which brings lots of difficulties to the diagnosis and treatment. Besides, there is a chance of co-infection<sup>[18]</sup>. Therefore, we intend to learn from the previous experience in dealing with the 2009 H1N1 influenza pandemic<sup>[19]</sup>, and compare it with the Omicron epidemic in Quanzhou<sup>[20]</sup>, which may better enable us to identify the two diseases.

Due to the younger age and fewer underlying diseases in the H1N1 group, the matched Omicron group also had such characteristics. The median age of the Omicron group was 21 [11,26] years, which was significantly lower than the median age of 36 [25,48] years in our previous study<sup>[20]</sup>. The younger age of the H1N1 group may be related to the characteristics of the virus<sup>[21]</sup> (all 127 H1N1 influenza patients were younger than 65 years old ). Since the outbreak of H1N1 influenza in China was in the early stage of epidemic and most patients had not been vaccinated,

the effect of vaccination in these two groups was not studied.

Our study found that fever (90.43% VS 34.35%;  $P < 0.001$ ), cough (68.70% VS 36.52%;  $P < 0.001$ ) and sore throat (41.74% VS 21.30%;  $P < 0.001$ ) were the most common symptoms in both groups, consistent with previous studies<sup>[22,23]</sup> that respiratory symptoms were the main symptoms. And the frequency of symptoms in the H1N1 group was higher than that in the Omicron group, which was also consistent with the previous study that the virulence of Omicron decreased and showed more asymptomatic<sup>[24]</sup>. The probability of muscle soreness (14.78 % VS 4.35 % ) was higher after Omicron infection, suggesting that Omicron was more likely to invade muscles. This may be related to the expression of ACE-2 receptor in skeletal muscle cell and other cells in muscle such as satellite cells, white blood cells, fibroblasts and endothelial cells. In addition to immune-mediated muscle damage, Omicron may also directly invade skeletal muscle and cause muscle damage<sup>[25]</sup>.

Omicron group had symptoms of olfactory loss and taste loss, which were major features different from H1N1 group. The possible mechanism is that Omicron adheres to the motor cilia with the help of ACE-2 receptor, breaks through the periciliary layer (PCL)<sup>[26]</sup>, infiltrates the olfactory epithelial tissue and induces local inflammatory response<sup>[27]</sup>, eventually causing microvascular and axonal changes<sup>[28]</sup> and affecting the expression of olfactory related genes<sup>[29]</sup>. And there are studies shows that in nasal tissue, the body 's response to SARS-CoV-2 is more extensive than that to influenza virus, including the maturation and activation of immune cells in both innate immunity and adaptive immunity<sup>[30]</sup>, which leads to a stronger immune response in the nasal mucosa and causes greater damage, making for a decline in olfactory function. Omicron can also enter specific epithelial taste cells through ACE-2 receptor and destroy normal taste function<sup>[31]</sup>. Or by affecting the oral symbiotic flora to change the immune status and induce cytokine storms, ultimately damaging the taste nerve and destroying the taste function<sup>[32]</sup>. Although there is no effective treatment for sensory loss<sup>[27]</sup>, most patients (>95%) can recover completely or nearly completely within half a year after the acute phase<sup>[33]</sup>.

Our study showed that H1N1 group had higher white blood cell count and CRP levels, which may suggest that the inflammatory response caused by H1N1 influenza is more severe. Different from previous studies<sup>[11]</sup>, the white blood cell count, lymphocyte count and CRP level in the Omicron group were within the normal range, which may be related to the younger age of the included population. The immunity of elderly patients is weak. With the increase of age, the diversity of T cells, which plays an important role in eliminating virus<sup>[34]</sup>, gradually decreases. And after 40 years old, it shows a trend of sharp decline<sup>[35]</sup>. Besides, there was a study showed that in Omicron patients, young people had higher levels of neutralizing antibodies<sup>[36]</sup>. The above differences may allow the virus in young patients to be cleared faster without significantly affecting the immune system, so that the lymphocyte count is still within the normal range, and the clinical symptoms of young patients are relatively mild compared to the elderly<sup>[37]</sup>. Omicron group had higher probability of LDH abnormality (29.57% VS 18.26%), which may be related to the wide distribution of ACE-2 receptor in body tissues<sup>[38]</sup>. Omicron may cause tissue damage through this receptor, leading to muscle soreness and abnormal LDH, but the specific mechanism is not clear.

In our study, whether H1N1 patients or Omicron patients, we found that the incidence of pneumonia in young patients was lower (3.48% VS 6.96%,  $P = 0.229$ ), and the symptoms were mainly upper respiratory tract infection. On the one hand, this may be related to the age

characteristics of the patient, the younger the patient, the lighter the condition<sup>[37]</sup>; on the other hand, it may be related to the relatively strong nasal and weakened pulmonary tropism of Omicron<sup>[26]</sup>. In addition, since H1N1 is one of the influenza viruses, there was a specific antiviral drug oseltamivir when it broke out. The high utilization rate of antiviral drugs (100.00 % VS 0.87 % ;  $p < 0.001$  ) may lead to low incidence of pneumonia. Besides, the use of antibiotics in the H1N1 group was higher than that in the Omicron group, indicating a higher probability of bacteria co-infection, which was consistent with the findings of previous studies<sup>[39]</sup>.

By Logistic regression analysis, we found if the patient had fever, cough, headache, or 1 unit ( $10^9/L$ ) increasement of white blood cell count, the probability of H1N1 was 18.689, 3.853, 16.649, 1.228 times higher than that of Omicron. This was obviously different from previous studies<sup>[40,41]</sup> in which there were more symptoms such as fever and cough after COVID-19 wild strain infection. H1N1 was less likely to cause muscle soreness and LDH abnormalities (the probability was 0.102 and 0.373 times that of Omicron, respectively). The specific reason may be related to the damage of Omicron to many body tissues including muscle tissue because of the widely distributed ACE-2 receptor<sup>[25,38]</sup>.

In our study, we found that the NAN time of Omicron group was significantly higher than that of H1N1 group ( 17 [ 14,20 ] VS 4 [ 3,5 ] days,  $P < 0.001$  ). Negative nucleic acid means that the patient is no longer the source of infection. And a longer NAN time shows that Omicron has a longer infectious time and spreads faster than H1N1 ( $R_0$  value :10 vs 2.75 )<sup>[42,43]</sup>. The reason may be related to the specific antibody production and the use of antiviral drugs. Due to the long-term seasonal influenza epidemic in the population, some people have cross-antibody against H1N1<sup>[44]</sup>. Moreover, specific anti-H1N1 virus drugs can quickly inhibit the virus, so that H1N1 virus can be quickly cleared in vivo. However, Omicron often has immune escape due to its strong mutation ability<sup>[45]</sup>, and the ability of neutralizing antibodies produced by the body to Omicron strain is significantly reduced<sup>[36]</sup>. Besides, the antiviral effect of Omicron is limited, which leads to a significant prolongation of virus clearance time. During the H1N1 epidemic, based on the use of the specific antiviral drug oseltamivir<sup>[19]</sup>, the symptoms of most patients were relieved quickly and the time of NAN was greatly shortened. Nevertheless, during the Omicron epidemic, since the Paxlovid had not been popularized in China, the use rate of antiviral drugs remained low<sup>[20]</sup>, which made the nucleic acid turn negative for a long time. In addition, this study analyzed the risk factors of NAN time in the two groups of patients and found that the antibiotic use and the increased white blood cell count suggested longer NAN time, which maybe due to the bacteria co-infection making the condition more complicated<sup>[46]</sup>. For Omicron patients, fever is positively correlated with the time of NAN. All these suggest that if H1N1 patients have elevated hemogram and Omicron patients have fever, we should be prepared for a longer course of disease and early use of antiviral drugs may be helpful for shortening the time of NAN<sup>[47,48]</sup>.

Our study also has some limitations: (1) All the included people are less than 65 years old, which cannot reflect the situation of high-risk people who has advanced age and many basic diseases. (2) Because this study was a retrospective study, some clinical data were missing, such as fever duration, antibodies, etc., making it hard to better compare the immune status of all patients. (3) Due to the large biological differences between H1N1 and Omicron, the influencing factors of NAN time are complicated and there must be bias in the analysis.

#### **Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

### **Ethics Statement**

The studies involving human participants were reviewed and approved by Ethics Committee of Fujian Provincial Hospital (ethics number: K2019-12-032) and the Ethics Committee of Quanzhou First Hospital (ethics number: No202212). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin. Written informed consent was obtained from the individual(s), and minor(s)' legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

### **Author contributions**

HRL, HL were responsible for funding acquisition. HRL, YWX were responsible for design conception. JBF were responsible for formal analysis. WZ, YSW, JBF performed data curation. HL, YSC were responsible for resources. BSX, NLX, ML, XPZ verified the underlying data. YSW, WZ prepared the original draft. All authors contributed to manuscript reviewing and editing. All authors had access to all data in the study and the corresponding author had final responsibility for the decision to submit the paper for publication

### **Acknowledgments**

This study was supported by grants from the National Science and Technology Major Special Project (No.2017Z 10103004), Natural Science Foundation of Fujian Province (No.2019J01178), and Fujian Provincial Hospital "Creating double High" Flint Fund project (No.2019HSJJ11).

### **Conflict of interest**

The authors declare no conflict of interest.

- [1] Weekly epidemiological update on COVID-19 - 25 January 2023[EB/OL]. [2023-01-28]. <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---25-january-2023>.
- [2] Causes and Consequences of Purifying Selection on SARS-CoV-2 | Genome Biology and Evolution | Oxford Academic[EB/OL]. [2023-01-31]. <https://academic.oup.com/gbe/article/13/10/evab196/6357039>.
- [3] Yeo M, Seo J, Lim J. The impact of the COVID-19 pandemic and the expansion of free vaccination policy on influenza vaccination coverage: An analysis of vaccination behavior in South Korea.[J]. PloS one, 2023, 18(2): e0281812.
- [4] Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study[J]. Lancet (London, England), 2022, 399(10323): 437-446.
- [5] Lundberg A L, Lorenzo-Redondo R, Ozer E A, et al. Has Omicron Changed the Evolution of the Pandemic? [J]. JMIR public health and surveillance, 2022, 8(1): e35763.
- [6] Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis - PMC[EB/OL]. [2022-11-11]. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126103/>.

- [7] Zhou F, Wang Y, Liu Y, et al. Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network[J]. *The European Respiratory Journal*, 2019, 54(2): 1802406.
- [8] Harrington W N, Kackos C M, Webby R J. The evolution and future of influenza pandemic preparedness[J]. *Experimental & Molecular Medicine*, 2021, 53(5): 737-749.
- [9] Dawood F S, Iuliano A D, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study[J]. *The Lancet. Infectious Diseases*, 2012, 12(9): 687-695.
- [10] Heo M, Jeong J H, Ju S, et al. Comparison of Clinical Features and Outcomes between SARS-CoV-2 and Non-SARS-CoV-2 Respiratory Viruses Associated Acute Respiratory Distress Syndrome: Retrospective Analysis[J]. *Journal of Clinical Medicine*, 2022, 11(8): 2246.
- [11] Yang Z, Lin D, Chen X, et al. Distinguishing COVID-19 From Influenza Pneumonia in the Early Stage Through CT Imaging and Clinical Features[J]. *Frontiers in Microbiology*, 2022, 13: 847836.
- [12] Bao S, Lu G, Kang Y, et al. A diagnostic model for serious COVID-19 infection among older adults in Shanghai during the Omicron wave[J]. *Frontiers in Medicine*, 2022, 9: 1018516.
- [13] Lu G, Zhang Y, Zhang H, et al. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave[J]. *Emerging Microbes & Infections*, 2022, 11(1): 2045-2054.
- [14] Silva E C G E, Schmitt A C B, Godoy C G de, et al. Ambulation capacity, age, immunosuppression, and mechanical ventilation are risk factors of in-hospital death in severe COVID-19: a cohort study[J]. *Clinics (Sao Paulo, Brazil)*, 2022, 77: 100075.
- [15] A H1N1 influenza diagnosis and treatment program (2009 trial version of the first edition ) [J]. *Infectious Disease Information*, 2009, 22(3): 121-123.
- [16] New coronavirus pneumonia diagnosis and treatment plan (trial version 9 ) [J]. *Chinese Journal of Viral Diseases*, 2022, 12(3): 161-169.
- [17] COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21[J]. *Lancet (London, England)*, 2022, 399(10334): 1513-1536.
- [18] Yue H, Zhang M, Xing L, et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak[J]. *Journal of Medical Virology*, 2020, 92(11): 2870-2873.
- [19] Chen Y S, Weng H, Pei X Y, et al. [Clinical features of 127 cases of novel influenza A (H1N1) infection in Fujian Province [J]. *Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases*, 2010, 33(2): 81-85.
- [20] Li H, Zhu X, Yu R, et al. The effects of vaccination on the disease severity and factors for viral clearance and hospitalization in Omicron-infected patients: A retrospective observational cohort study from recent regional outbreaks in China[J]. *Frontiers in Cellular and Infection Microbiology*, 2022, 12: 988694.
- [21] Karageorgopoulos D E, Vouloumanou E K, Korbila I P, et al. Age distribution of cases of 2009 (H1N1) pandemic influenza in comparison with seasonal influenza[J]. *PloS One*, 2011, 6(7): e21690.
- [22] Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans[J]. *New England*



- Journal of Medicine, 2009, 360(25): 2605-2615.
- [23] Tiecco G, Storti S, Degli Antoni M, et al. Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review[J]. International Journal of Molecular Sciences, 2022, 23(4): 1987.
- [24] Jiao Yang, Qiangru Huang, Qing Wang, et al. Research progress on the proportion and characteristics of asymptomatic infection with novel coronavirus [J]. National Medical Journal of China, 2022, 102(46): 3715-3718.
- [25] Paliwal V K, Garg R K, Gupta A, et al. Neuromuscular presentations in patients with COVID-19[J]. Neurological Sciences, 2020, 41(11): 3039.
- [26] Wu C T, Lidsky P V, Xiao Y, et al. SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming[J]. Cell, 2023, 186(1): 112-130.e20.
- [27] Khurana K, Singh C V. Management of Anosmia in COVID-19: A Comprehensive Review[J]. Cureus, 14(10): e30425.
- [28] Ho C Y, Salimian M, Hegert J, et al. Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19[J]. JAMA Neurology, 2022, 79(6): 544-553.
- [29] Zazhytska M, Kodra A, Hoagland D A, et al. Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia[J]. Cell, 2022, 185(6): 1052-1064.e12.
- [30] Alfi O, Yakirevitch A, Wald O, et al. Human Nasal and Lung Tissues Infected Ex Vivo with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract[J]. Journal of Virology, 95(14): e00130-21.
- [31] Human Type II Taste Cells Express Angiotensin-Converting Enzyme 2 and Are Infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) - PMC[EB/OL]. [2022-11-29]. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179718/>.
- [32] Xu W, Sunavala-Dossabhoy G, Spielman A I. Chemosensory loss in COVID-19[J]. Oral Diseases.
- [33] Tan B K J, Han R, Zhao J J, et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves[J]. The BMJ, 2022, 378: e069503.
- [34] Kumar B V, Connors T J, Farber D L. Human T Cell Development, Localization, and Function throughout Life[J]. Immunity, 2018, 48(2): 202-213.
- [35] Simnica D, Akyüz N, Schliffke S, et al. T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors[J]. Oncoimmunology, 2019, 8(11): e1644110.
- [36] Liang D, Zhang G, Huang M, et al. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum[J]. Pathogens (Basel, Switzerland), 2022, 11(12): 1531.
- [37] Davies N G, Klepac P, Liu Y, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics[J]. Nature Medicine, 2020, 26(8): 1205-1211.
- [38] Li R, Qin C. Expression pattern and function of SARS-CoV-2 receptor ACE2[J]. Biosafety and Health, 2021, 3(6): 312-318.
- [39] Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August

- 2009[J]. MMWR. Morbidity and mortality weekly report, 2009, 58(38): 1071-1074.
- [40] Lv D, Ying Q, He Y, et al. Differential diagnosis of coronavirus disease 2019 pneumonia or influenza A pneumonia by clinical characteristics and laboratory findings[J]. Journal of Clinical Laboratory Analysis, 2021, 35(2).
- [41] Li P, Wang Y, Peppelenbosch M P, et al. Systematically comparing COVID-19 with the 2009 influenza pandemic for hospitalized patients[J]. International Journal of Infectious Diseases, 2021, 102: 375-380.
- [42] Brooks W A, Goswami D, Rahman M, et al. Influenza is a major contributor to childhood pneumonia in a tropical developing country[J]. The Pediatric Infectious Disease Journal, 2010, 29(3): 216-221.
- [43] Burki T K. Omicron variant and booster COVID-19 vaccines[J]. The Lancet. Respiratory Medicine, 2022, 10(2): e17.
- [44] Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus[J]. The New England Journal of Medicine, 2009, 361(20): 1945-1952.
- [45] Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies[J]. Nature, 2022, 602(7898): 657-663.
- [46] Krumbein H, Kümmel L S, Fragkou P C, et al. Respiratory viral co-infections in patients with COVID-19 and associated outcomes: A systematic review and meta-analysis[J]. Reviews in Medical Virology, 2022.
- [47] Zhou B tong, Fan Y ming, Li T ming, et al. Clinical features of initial cases of 2009 pandemic influenza A (H1N1) in Macau, China[J]. Chinese Medical Journal, 2010, 123(19): 2651-2654.
- [48] Weng C, Xie R, Han G, et al. Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients[J]. Infectious Diseases and Therapy, 2023: 1-14.

### **TABLE 1 Baseline information of H1N1 group and Omicron group.**

### **TABLE 2 Comparison of clinical characteristics between the H1N1 and Omicron group.**

For descriptive analysis, we presented data as median [interquartile range (IQR)] for continuous parameters and as frequency (percentage) for categorical variables. Wilcoxon rank sum testing was employed for numerical variables and Fisher's precision probability test was adopted for categorical variables. Statistical analysis was performed using SPSS 25.0 data analysis software.

### **TABLE 3 Analysis of risk factors between H1N1 group and Omicron group**

Multivariate logistic regression analysis was performed with Omicron group as reference. Missing data are processed by multiple interpolation.

### **TABLE 4 Analysis of influencing factors for the time for nucleic acid negativization (NAN)**

The factors affecting NAN time in the H1N1 group and Omicron group were analyzed by multiple linear regression. Indices of statistical differences ( $P < 0.200$ ) univariate analysis were included in the multivariate regression analysis. "-" indicates that too many or too few values to perform single factor regression analysis. Missing data are processed by multiple interpolation.

### **Figure 1**

The abscissa of each point represents the frequency (%) of the symptom shown in the H1N1 group, and the ordinate represents the frequency (%) of the symptom shown in the Omicron group. The dotted line indicates that the abscissa and the ordinate are equal here. The arrow indicates that there are completely coincident points here. Fever (90.43% VS 34.35%;  $P < 0.001$ ), cough (68.70% VS 36.52%;  $P < 0.001$ ) and sore throat (41.74% VS 21.30%;  $P < 0.001$ ) were the most common symptoms in both groups, and Omicron group has a lower frequency of symptoms.

## **Figure 2**

Box plot graphs revealing statistically significant differences in both the white blood cell (WBC) counts (A) and CRP levels (B) between Omicron group and H1N1 group. Most patients with both diseases had normal WBC counts and CRP levels; however, the overall values in H1N1 group were higher than those in Omicron ( $p < 0.05$ ).

**TABLE 1 Baseline information of H1N1 group and Omicron group.**

	H1N1 group		Omicron group	
	N1	Frequency/IQR	N2	Frequency/IQR
Total(n)	115	100.00%	230	100.00%
<b>Age</b>				
median age		21[11,26]		21[11,26]
< 18	42	36.52%	87	37.83%
18-65	73	63.48%	143	62.17%
> 65	0	0.00%	0	0.00%
<b>Sex</b>				
Male	65	56.52%	130	56.52%
Female	50	43.48%	100	43.48%
<b>Underlying diseases</b>				
Pregnancy	0	0.00%	0	0.00%
Hypertension	0	0.00%	0	0.00%
Diabetes	0	0.00%	0	0.00%
Cardiovascular diseases	0	0.00%	0	0.00%
Chronic liver diseases	0	0.00%	0	0.00%
Respiratory diseases	0	0.00%	0	0.00%
Neurological diseases	0	0.00%	0	0.00%
Hematological diseases	0	0.00%	0	0.00%
Chronic kidney diseases	0	0.00%	0	0.00%
Metabolic diseases	0	0.00%	0	0.00%
Tumor	0	0.00%	0	0.00%
<b>Vaccine status (%)</b>				
No vaccination	-	-	38	16.52%
One-dose	-	-	15	6.52%
Two-dose	-	-	117	50.87%
Three-dose	-	-	60	26.09%

**TABLE 2 Comparison of clinical characteristics between the H1N1 and Omicron group.**

	H1N1 group		Omicron group		P-value
total(n)	115	100.00%	230	100.00%	
<b>clinical features</b>					
Fever n (%)	104	90.43%	79	34.35%	<0.001
Nasal congestion n (%)	14	12.17%	4	1.74%	<0.001
Sore throat n (%)	48	41.74%	49	21.30%	<0.001
Olfactory loss n (%)	0	0.00%	16	6.96%	0.002
Taste loss n (%)	0	0.00%	7	3.04%	0.100
Cough n (%)	79	68.70%	84	36.52%	<0.001
Expectoration n (%)	30	26.09%	33	14.35%	0.012
Fatigue n (%)	15	13.04%	36	15.65%	0.630
Dyspnea n (%)	0	0.00%	7	3.04%	0.100
Diarrhea n (%)	1	0.87%	9	3.91%	0.174
Vomiting n (%)	1	0.87%	0	0.00%	0.333
Headache n (%)	18	15.65%	2	0.87%	<0.001
Muscle soreness n (%)	5	4.35%	34	14.78%	0.004
<b>Laboratory diagnostics</b>					
WBC count (10 <sup>9</sup> /L), Median(IQR)	5.49	[4.40,6.93]	4.85	[3.76,6.45]	0.008
Lymphocyte count (10 <sup>9</sup> /L), Median(IQR)	1.51	[1.09,2.02]	1.58	[1.09,2.53]	0.161
Abnormal LDH, n (%)	21	18.26%	68	29.57%	0.023
CRP (mg/L), Median(IQR)	4.6	[2.30,10.45]	3.23	[0.51,6.84]	0.001
<b>Imaging diagnostics</b>					
pneumonia n (%)	4	3.48%	16	6.96%	0.229
<b>Treatment and prognostic indicator</b>					
Antibiotic usage rate, n(%)	16	13.91%	2	0.87%	<0.001
Antiviral usage rate, n(%)	115	100.00%	2	0.87%	<0.001
Nucleic acid negative time (d), Median(IQR)	4	[3,5]	17	[14,20]	<0.001

For descriptive analysis, we presented data as median [interquartile range (IQR)] for continuous parameters and as frequency (percentage) for categorical variables. Wilcoxon rank sum testing was employed for numerical variables and Fisher's precision probability test was adopted for categorical variables. Statistical analysis was performed using SPSS 25.0 data analysis software.

**TABLE 3 Analysis of risk factors between H1N1 group and Omicron group**

Factor	B	SE	Wald	P	OR	95%CI
Fever	2.954	0.396	55.538	< 0.001	19.179	8.82-41.708
Nasal congestion	1.179	0.76	2.403	0.121	3.25	0.732-14.418
Sore throat	0.363	0.354	1.048	0.306	1.437	0.718-2.878
Cough	1.264	0.367	11.868	0.001	3.541	1.725-7.270
Expectoration	-0.193	0.459	0.176	0.675	0.825	0.335-2.030
Headache	2.753	0.983	7.852	0.005	15.695	2.288-107.679
Muscle soreness	-2.971	0.695	18.281	< 0.001	0.051	0.013-0.200
WBC count	0.174	0.075	5.39	0.02	1.19	1.027-1.378
Abnormal LDH	-0.934	0.359	6.759	0.009	0.393	0.194-0.795
CRP	0.009	0.018	0.287	0.592	1.009	0.975-1.045

Multivariate logistic regression analysis was performed with Omicron group as reference. Missing data are processed by multiple interpolation.


**TABLE 4 Analysis of influencing factors for the time for nucleic acid negativization (NAN)**

Variables	H1N1				Omicron			
	Univariate		Multivariate		Univariate		Multivariate	
	B	P value	B (95%CI)	P value	B	P value	B (95%CI)	P value
Fever	0.625	0.353			1.583	0.023	1.529 (0.149,2.909)	0.030
Nasal congestion	-0.133	0.826			0.816	0.749		
Sore throat	-0.009	0.982			0.066	0.935		
Olfactory loss	-	-			1.064	0.416		
taste loss	-	-			1.233	0.525		
Cough	-0.038	0.929			0.514	0.458		
Expectoration	0.08	0.859			0.379	0.690		
Fatigue	-1.503	0.009	-1.589 (-2.646, -0.532)	0.004	1.346	0.141	1.077 (-0.724,2.878)	0.240
Dyspnea	-	-			0.054	0.978		
Diarrhea	0.531	0.803			0.054	0.975		
Vomiting	-2.496	0.241			-	-		
Headache	-1.089	0.044	-0.986 (-1.978, -0.006)	0.051	1.566	0.663		
Muscle soreness	0.968	0.318			1.166	0.214		
WBC count	0.325	0.001	0.217 (0.028,0.406)	0.025	-0.063	0.673		
Lymphocyte count	0.074	0.657			-0.093	0.665		
Abnormal LDH	0.639	0.170	0.182 (-0.666,1.029)	0.672	-0.015	0.983		
CRP	0.049	0.026	0.03 (-0.011,0.071)	0.152	0.040	0.297		

Pneumonia (Imaging)	2.099	0.05	1.473 (-0.525,3.470)	0.147	-0.347	0.791		
Antibiotic usage rate	1.809	0.001	1.076 (-0.100,2.252)	0.072	5.601	0.118	6.301 (-0.666,13.267)	0.076
Antiviral usage rate	-	-			-2.469	0.491		

The factors affecting NAN time in the H1N1 group and Omicron group were analyzed by multiple linear regression. Indices of statistical differences ( $P < 0.200$ ) univariate analysis were included in the multivariate regression analysis. “-” indicates that too many or too few values to perform single factor regression analysis. Missing data are processed by multiple interpolation.





1. Fever
2. Nasal congestion
3. Sore throat
4. Olfactory loss
5. Taste loss
6. Cough
7. Expectoration
8. Fatigue
9. Dyspnea
10. Diarrhea
11. Vomiting
12. Headache
13. Muscle soreness

